|
|
|
|
|
02.07.25 - 15:24
|
Caribbean: TotalEnergies Expands its Partnership with AES from LNG to Renewable Energy (Business Wire)
|
|
|
TotalEnergies expands its long-standing LNG partnership with AES on renewable and battery storage in the Caribbean
TotalEnergies has purchased 50% of AES renewable portfolio in the Dominican Republic, following a previous acquisition of 30% in AES' Puerto Rican assets
The combined 1.5 GW portfolio will produce 2.5 TWh/y of renewable electricity
PARIS--(BUSINESS WIRE)--TotalEnergies (Paris:TTE) (LSE:TTE) (NYSE:TTE) announces the closing of its acquisition of a 50% stake in the solar, wind and Battery Energy Storage Systems (BESS) portfolio of AES Dominicana Renewables Energy. This deal follows TotalEnergies' 2024 acquisition of a 30% share in AES solar and battery assets currently under construction in Puerto Rico. The combined portfolio now exceeds 1.5 GW of renewable energy and BESS capacity across the Caribbean.
These transactions advance TotalEnergies' multi-energy strategy in a region where it is a key player in the liquefied natural gas (LNG) value chain.
Dominican Republic: TotalEnergies acquires...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
11.06.25 - 15:15
|
Lexarias DehydraTECH-Liraglutide Human GLP-1 Clinical Study Supports Pathway to Potential FDA Registration as an Orally-Delivered Capsule (The Newswire)
|
|
|
Oral DehydraTECH-liraglutide showed a pronounced reduction in adverse events (“AEs”) as compared to injected liraglutide (Saxenda®)
Lexaria has now demonstrated, in distinct human clinical studies, clear reductions in AEs utilizing its patented DehydraTECH technology with all of the three major GLP-1 drugs sold in the world today: liraglutide, semaglutide and tirzepatide
Kelowna, British Columbia – June 11, 2025 – TheNewswire – Lexaria Bioscience Corp. (Nasdaq: LEXX, LEXXW) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, is pleased to announce that human study GLP-1-H25-5 (the “Study”) which compared oral capsules of DehydraTECH-liraglutide to injected Saxenda®-branded liraglutide has been successfully completed with partial results now available.
In distinct clinical human studies, Lexaria has now demonstrated clear reductions in AEs utilizing oral DehydraTECH versions of all three of the major GLP-1 drugs sold in the worl...
|
|
|
|
|
|
|
|
|
|
|
28.05.25 - 19:00
|
AES (AES) Could Be a Great Choice (Zacks)
|
|
|
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does AES (AES) have what it takes? Let's find out....
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
